Fig. 1
From: Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Long-term BTKi treatment normalises lymphocyte subset frequency and reduces PD-1 expression. Frequency of CD19 + B cells (A), CD3 + T cells (B) and CD4:CD8 ratio (C) in PBMC from CLL patients collected prior to treatment (baseline), after long-term treatment of ibrutinib (n = 7) or zanubrutinib (n = 8) and age-matched healthy donors (HD, n = 7). PD-1 median fluorescence intensity (MFI) on CD8 + (D) and CD4 + (E) T cells